Haematex Research, Sydney, Australia.
Université Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Institute for Life Sciences (NARILIS), Haematology Laboratory, Yvoir, Belgium.
Thromb Res. 2019 Jul;179:69-72. doi: 10.1016/j.thromres.2019.04.028. Epub 2019 May 2.
Clotting test results are currently not useful for estimating direct oral anti-coagulant (DOAC) concentrations because baseline results vary. DOAC Stop is a DOAC extracting agent with no effect on clotting factors. We investigated if aPTT (activated partial thromboplastin time) and dRVVT (dilute Russells viper venom time) results might correlate better with DOAC concentrations if results after DOAC extraction were used to estimate a "before/after" value (Correction Ratio).
We used activated partial thromboplastin time (aPTT, PTT-LA) and dilute Russells viper venom time clotting test (dRVVT) results previously recorded on DOAC patient plasmas (25 dabigatran, 15 apixaban, 19 rivaroxaban) without known thrombotic risk factors before and after DOAC extraction. DOAC concentrations had been determined by standard chromogenic assays.
Correlations between aPTT and dabigatran, apixaban, and rivaroxaban concentrations were initially poor (0.64, 0.15 and 0.39 respectively). However, they improved significantly to 0.94, 0.89 and 0.80 when the ratios of initial aPTT to the aPTT obtained after DOAC extraction were plotted against DOAC concentration. Still better correlations (0.99, 0.97, 0.95) and much higher sensitivities to the DOACs were obtained when dRVVT (LA Confirm) tests were used following this procedure on the same samples.
The correlations of aPTT and dRVVT tests with DOAC concentrations were significantly improved by using the ratio of result "before" to those "after" DOAC extraction. The results indicate that dRVVT (especially LA Confirm) and similar tests might be useful for determining DOAC concentrations more reliably and with better sensitivity than currently possible with clotting tests.
目前凝血检测结果对于估算直接口服抗凝剂(DOAC)的浓度并不有用,因为基础值结果存在差异。DOAC Stop 是一种 DOAC 提取剂,对凝血因子无影响。我们研究了如果使用 DOAC 提取后的检测结果来估算“前后”值(校正比),是否可以使 aPTT(活化部分凝血活酶时间)和 dRVVT(稀释 Russell 蝰蛇毒时间凝血试验)结果与 DOAC 浓度相关性更好。
我们使用之前记录的 DOAC 患者血浆(25 例达比加群、15 例阿哌沙班、19 例利伐沙班)的活化部分凝血活酶时间(aPTT,PTT-LA)和稀释 Russell 蝰蛇毒时间凝血试验(dRVVT)结果,这些血浆在 DOAC 提取前后均无已知的血栓形成风险因素。DOAC 浓度已通过标准显色法测定。
aPTT 与达比加群、阿哌沙班和利伐沙班浓度的相关性最初较差(分别为 0.64、0.15 和 0.39)。然而,当将初始 aPTT 与 DOAC 提取后获得的 aPTT 比值与 DOAC 浓度作图时,其相关性显著提高至 0.94、0.89 和 0.80。当在相同样本上按照该程序使用 dRVVT(LA Confirm)检测时,得到了更好的相关性(0.99、0.97、0.95)和对 DOAC 更高的敏感性。
通过使用 DOAC 提取前后的比值,aPTT 和 dRVVT 检测与 DOAC 浓度的相关性得到了显著改善。结果表明,dRVVT(尤其是 LA Confirm)和类似的检测方法可能比目前的凝血检测更可靠、更灵敏地确定 DOAC 浓度。